Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized
- PDF / 930,040 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 64 Downloads / 202 Views
ORIGINAL CONTRIBUTION
Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial Liping Yang1,2 · Yun Qiu1 · Wenhua Ling1 · Zhaomin Liu1 · Lili Yang1 · Changyi Wang2 · Xiaolin Peng2 · Li Wang2 · Jianying Chen3 Received: 20 April 2020 / Accepted: 28 August 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Background Epidemiological studies have suggested that adipsin and visfatin are associated with the development of type 2 diabetes. This is the first study to investigate the effects of supplementation with purified anthocyanins on serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes. Methods A total of 160 participants with prediabetes or newly diagnosed diabetes (40–75 years old) were given 320 mg anthocyanins or placebo daily for 12 weeks in a randomized trial. Serum adipsin, serum visfatin, lipids and glycated hemoglobin A1c (HbA1c) were measured. The areas under the curve (AUCs) for glucose, insulin and C-peptide were determined before-and after-treatment by a standard 3-h 75 g oral glucose tolerance test (OGTT). Results Relatively significant increases in serum adipsin (net change 0.15 µg/mL [0.03, 0.27], p = 0.018) and decreases in visfatin (−3.5 ng/mL [−6.69, −0.31], p = 0.032) were observed between the anthocyanins and placebo groups. We also observed significant improvements in HbA1c (−0.11% [−0.22, −0.11], p = 0.033), apolipoprotein A-1 (apo A-1) (0.12 g/L [0.03, 0.21], p = 0.012) and apolipoprotein B (apo B) (−0.07 g/L [−0.14, −0.01], p = 0.033) in response to the anthocyanins intervention. Conclusion Purified anthocyanins supplementation for 12 weeks increased serum adipsin and decreased serum visfatin in patients with prediabetes or newly diagnosed diabetes. Trial registration ClinicalTrials.gov, identifier: NCT02689765. Keywords Anthocyanin · Adipsin · Visfatin
Introduction
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00394-020-02379-x) contains supplementary material, which is available to authorized users. * Liping Yang [email protected] 1
Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, 74th ZhongShan Road II, GuangZhou 510080, PR China
2
Center for Chronic Disease Control, Nanshan, ShenZhen, PR China
3
GuangDong Province, BaiYun Hospital, YueXiu District, GuangZhou, PR China
The prevalence of type 2 diabetes mellitus (T2DM) has reached pandemic levels and has become a major health challenge in numerous countries [1]. Obesity is one of the main risk factors for the development of type 2 diabetes. Adipose tissue is known to be an active endocrine organ that secretes adipokines involved in the regulation of energy homeostasis and the immune response [2]. In recent years, adipocyte dysfunction has been frequently associated with the development of insulin resistance and T2DM. Growing evidence
Data Loading...
